FDA grants orphan drug status to novel brain cancer treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
Glioma
Brainchild Bio planning pivotal trial of CAR T-cell therapy for DIPG
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
Chimerix asks FDA to approve oral dordaviprone as glioma treatment
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
Glioma therapy THIO granted FDA rare pediatric disease designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
Phase 2 study of G207 for children with recurrent brain cancer opens
Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based therapy, for pediatric recurrent high-grade…
Study IDs ways IDH-related brain tumors become more aggressive
Researchers have uncovered genetic changes that may explain why certain brain tumors, known as gliomas, that are associated with IDHÂ gene mutations start off as…
Scientists discover tissue differences in brain cancer in children
U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children — are generally softer than normal…
Virus-based MB-108 named FDA orphan drug for malignant glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, an experimental virus-based therapy that Mustang Bio is developing for…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment